Brief: Lytix Biopharma Q1 Operating Loss Narrows To NOK 13.4 Mln
15/05/2025 06:16
May 15 (Reuters) - Lytix Biopharma AS LYTIX.OL: Q1 OPERATING LOSS NOK 13.4 MILLION VERSUS LOSS NOK 18.7 MILLION YEAR AGO Source text: ID:nWkr2CJ5qF Further company coverage: LYTIX.OL (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Lytix Biopharma AS
See all newsBrief: Lytix Biopharma Q3 Loss Widens To NOK 23.3 Mln
Brief: Lytix Biopharma Announces Interim Data On Neoadjuvant Treatment Of Melanoma
Brief: Lytix Biopharma Q1 Operating Loss Narrows To NOK 13.4 Mln
Brief: Lytix Biopharma Q4 Total Operating Income Nok 377,000
Brief: Lytix Biopharma Gets Notice Of Allowance For US Patent Application For Ltx-315 Clinical Program